- Home
- AMGN vs COF Comparison
AMGN vs COF Comparison
Compare AMGN & COF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- COF
- Stock Information
- Founded
- AMGN 1980
- COF 1988
- Country
- AMGN United States
- COF United States
- Employees
- AMGN N/A
- COF N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- COF Major Banks
- Sector
- AMGN Health Care
- COF Finance
- Exchange
- AMGN Nasdaq
- COF Nasdaq
- Market Cap
- AMGN 150.8B
- COF 144.9B
- IPO Year
- AMGN N/A
- COF 1994
- Fundamental
- Price
- AMGN $295.71
- COF $211.23
- Analyst Decision
- AMGN Buy
- COF Buy
- Analyst Count
- AMGN 18
- COF 16
- Target Price
- AMGN $326.94
- COF $245.06
- AVG Volume (30 Days)
- AMGN 2.8M
- COF 3.3M
- Earning Date
- AMGN 10-29-2025
- COF 10-21-2025
- Dividend Yield
- AMGN 3.22%
- COF 1.14%
- EPS Growth
- AMGN 110.88
- COF N/A
- EPS
- AMGN 12.23
- COF N/A
- Revenue
- AMGN $34,917,000,000.00
- COF $23,773,000,000.00
- Revenue This Year
- AMGN $8.94
- COF $94.82
- Revenue Next Year
- AMGN $1.69
- COF $18.43
- P/E Ratio
- AMGN $24.14
- COF N/A
- Revenue Growth
- AMGN 12.88
- COF N/A
- 52 Week Low
- AMGN $253.30
- COF $143.22
- 52 Week High
- AMGN $335.88
- COF $232.45
- Technical
- Relative Strength Index (RSI)
- AMGN 58.97
- COF 35.59
- Support Level
- AMGN $290.21
- COF $211.13
- Resistance Level
- AMGN $297.63
- COF $215.76
- Average True Range (ATR)
- AMGN 6.81
- COF 4.99
- MACD
- AMGN 1.96
- COF -1.35
- Stochastic Oscillator
- AMGN 78.87
- COF 12.25
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About COF Capital One Financial Corporation
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending. Following the acquisition of Discover in 2025, the firm also has a modest personal loan business, though credit card lending still provides the majority of the bank's revenue.